DEF 14A

Company

Xeris Biopharma Holdings, Inc.

Filed

April 26, 2023

Period of Report

December 31, 2022

Accession Number

0001867096-23-000056

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →